Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19816871 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8441499 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8811913 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL415770 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8814164 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL7201423 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL436881 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL274488 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL8812283 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL | |
| SCHEMBL3653121 | 1.00 | LMNA (0.68) | LMNAALDH1A1TSHREPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3488000-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA Textiles (U.K.) Limited (GB) | 2019-05-29 | — | — | EP | claimed |
| WO-2018022633-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA TEXTILES (U.K.) LIMITED (GB) | 2018-02-01 | — | — | WO | claimed |
| EP-3488000-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA Textiles (U.K.) Limited (GB) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018022633-A1 | METHODS AND MATERIALS FOR BIOSYNTHESIZING MULTIFUNCTIONAL, MULTIVARIATE MOLECULES VIA CARBON CHAIN MODIFICATION | INVISTA TEXTILES (U.K.) LIMITED (GB) | 2018-02-01 | — | — | WO | disclosed |
| US-20110144064-A1 | Inhibitors of Kynurenine Aminotransferase and Uses Therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| EP-1954665-A1 | INHIBITORS OF KYNURENINE AMINOTRANSFERASE AND USES THEREFOR | The University of Maryland, Baltimore (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007064784-A1 | INHIBITORS OF KYNURENINE AMINOTRANSFERASE AND USES THEREFOR | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-0057975-B1 | PROCESS FOR PRODUCING POLYCONDENSATES OF OMEGA-OXYPENTADECONOIC ACID | Takasago Perfumery Co., Ltd. (JP) | 1985-08-14 | — | — | EP | disclosed |
| US-4419292-A | Process for producing polycondensates of ω-oxypentadecanoic acid | TAKASAGO PERFUMERY CO., LTD. (JP) | 1983-12-06 | — | — | US | disclosed |
| EP-0057975-A1 | Process for producing polycondensates of omega-oxypentadeconoic acid | Takasago Perfumery Co., Ltd. (JP) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144064-A1 | Inhibitors of Kynurenine Aminotransferase and Uses Therefor | GOT1, GOT2, AADAT | LMNA 4447/4885ALDH1A1 887/4885TSHR 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.